Gemtuzumab ozogamicin and novel antibody-drug conjugates in clinical trials for acute myeloid leukemia

Targeted agents are increasingly used for the therapy of acute myeloid leukemia (AML). Gemtuzumab ozogamicin (GO) is the first antibody-drug conjugate (ADC) approved for induction therapy of AML. When used in fractionated doses, GO combined with the conventional cytarabine/anthracycline-based induct...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Bo, Liu, Delong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824118/
https://www.ncbi.nlm.nih.gov/pubmed/31695916
http://dx.doi.org/10.1186/s40364-019-0175-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824118/
https://www.ncbi.nlm.nih.gov/pubmed/31695916
http://dx.doi.org/10.1186/s40364-019-0175-x

Ejemplares similares